Answers are grounded in this paper and cite their sources.
This review discusses small molecule antibiotics approved for clinical use in the time frame 2010-2022. This time span saw the approval of four synthetic antibiotics (bedaquiline, pretomanid, delafloxacin, tedizolid), nine natural product derivatives (ceftaroline fosamil, cefiderocol, plazomicin, omadacycline, eravacycline, sarecycline, lefamulin, dalbavancin, oritavancin), and one natural product (fidaxomicin).
No takes yet. Share an insight, caveat, or question.
Jung et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: